8-K: Prestige Consumer Healthcare Reports FY26 Results, Acquires LaCorium Health

Prestige Consumer Healthcare announced fiscal year 2026 results, reporting $1,088.7 million in revenue and $4.38 in adjusted diluted EPS, alongside the agreement to acquire Australian therapeutic skincare company LaCorium Health for approximately $150 million.

Summary

• Prestige Consumer Healthcare reported fiscal year 2026 revenues of $1,088.7 million, a decrease of 4.3% from the prior year, attributed to challenges in eye care production and shipping disruptions.
• The company achieved $246.4 million in free cash flow for fiscal year 2026, an increase from the prior year.
• Reported diluted EPS for fiscal year 2026 was $3.91, with adjusted diluted EPS at $4.38.
• Prestige Consumer Healthcare has entered into an agreement to acquire LaCorium Health, a leader in Australian therapeutic skincare, for approximately $150 million, expected to close in the second quarter of fiscal year 2027.
• The company provided an outlook for fiscal year 2027, projecting organic revenue growth of 1% to 3% and adjusted diluted EPS between $4.42 and $4.51, excluding acquisition impacts.
• For fiscal year 2027, the company anticipates free cash flow of $250 million or more.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report with significant headwinds in revenue and EPS compared to the prior year, partially offset by strong free cash flow generation and a strategic acquisition that offers future growth potential.

Positives

• Generated $246.4 million in free cash flow in fiscal year 2026, an increase from the prior year.
• Announced the acquisition of LaCorium Health, a strategic move to expand into therapeutic skincare with strong brand recognition in Australia.
• LaCorium Health is expected to generate approximately $12 million in EBITDA including synergies and is experiencing double-digit net sales growth.
• Fiscal year 2027 outlook projects organic revenue growth of 1% to 3% and adjusted diluted EPS of $4.42 to $4.51.
• Anticipates free cash flow of $250 million or more for fiscal year 2027.
• Medium-term outlook projects approximately 10% annual CAGR for revenue growth and 8% for EPS growth over the next three years.
• Expects to generate approximately $900 million in aggregate free cash flow over the next three years.
• Opportunistically repurchased 2.3 million shares for approximately $156 million in fiscal year 2026.

Negatives

• Reported revenues decreased by 4.3% to $1,088.7 million in fiscal year 2026 compared to the prior year.
• Fourth quarter revenues decreased by 5.0% to $281.6 million compared to the prior year.
• Adjusted diluted EPS for fiscal year 2026 was $4.38, a decrease from $4.52 in the prior year.
• Adjusted diluted EPS for the fourth quarter was $1.23, down from $1.32 in the prior year.
• Limited ability to supply demand for Clear Eyes due to production constraints at the Pillar5 facility impacted revenue.
• Shipping disruptions in the Middle East affected international segment revenues in the fourth quarter.
• Net income for fiscal year 2026 was $190.3 million, down from $214.6 million in the prior year.

Risks

• Continued volatility in the consumer backdrop is expected to impact spending.
• Variability in eye care supply is anticipated in fiscal year 2027 as production ramps up and safety stocks are rebuilt.
• Potential for continued volatile consumer backdrop impacting fiscal year 2027 outlook.
• Fluctuating foreign exchange rates could impact results.
• Competitive pressures within the consumer healthcare market.
• Potential for inflationary cost increases and supply chain disruptions.
• Risks associated with integrating the newly acquired LaCorium Health business.
• The company's ability to manage and mitigate energy costs moving forward.

Future Outlook

For fiscal year 2027, Prestige Consumer Healthcare anticipates organic revenue growth of 1% to 3% and adjusted diluted EPS between $4.42 and $4.51. Free cash flow is projected to be $250 million or more. The company expects to provide an updated outlook after the completion of the Breathe Right and LaCorium Health acquisitions. Over the next three years, the company projects approximately 10% annual revenue growth CAGR, 8% EPS growth CAGR, and free cash flow approaching $900 million in aggregate.

Management Comments

• Our fiscal 2026 demonstrated the resilience of our business model in a challenging consumer backdrop.
• Our diversified portfolio of leading brands with deep consumer heritage supports a durable financial profile and drives strong, growing free cash flow.
• As we begin fiscal 2027, we anticipate our proven financial model and diversified portfolio of leading, trusted brands will result in sales growth approximate to our long-term expectations.
• We anticipate adjusted diluted EPS of $4.42 to $4.51, following sales growth and adjusted free cash flow of $250 million or more.
• Regarding recent fluctuations in energy costs, just like other inflationary periods of the past, we plan to leverage our leading portfolio, diverse supply chain, and agile operating model to manage and mitigate these costs as they arise in our fiscal 2027 and moving forward.

Industry Context

StockSavvy.ai notes that Prestige Consumer Healthcare's results reflect broader trends in the consumer healthcare sector, including supply chain challenges impacting key product lines like eye care, alongside strategic acquisitions aimed at portfolio diversification and growth in specialized segments like therapeutic skincare.

Comparison to Industry Standards

• The reported revenue decrease of 4.3% for FY26 is a concern when compared to the generally stable to growing nature of the consumer healthcare market, which often sees low-to-mid single-digit growth for established brands.
• The company's adjusted diluted EPS of $4.38 for FY26, while showing a slight decrease from the prior year, remains within a competitive range for mature consumer goods companies, but lags behind faster-growing peers in niche segments.
• The acquisition of LaCorium Health, with its strong market position in Australian therapeutic skincare, aligns with industry trends of consolidation and expansion into higher-margin, specialized product categories, similar to moves seen by competitors like Johnson & Johnson's consumer health division or Haleon.
• The projected fiscal year 2027 organic revenue growth of 1% to 3% is conservative and aligns with a mature market, but the company aims to exceed this with its medium-term outlook of 10% CAGR, which would place it among higher-growth companies if achieved, contingent on successful integration of acquisitions and recovery in its eye care segment.

Stakeholder Impact

• Shareholders may see a short-term negative impact due to the reported revenue and EPS declines compared to the prior year, but potential long-term gains from the LaCorium Health acquisition and future growth projections.
• Employees may face uncertainty due to the revenue decline, but the acquisition and focus on operational improvements could lead to new opportunities.
• Customers may experience continued limited availability of certain eye care products while production is optimized, but the company is focused on quality and increased capacity.
• Suppliers may be impacted by the overall revenue decrease, but the acquisition of LaCorium Health could lead to new business opportunities.

Next Steps

• Complete the acquisition of LaCorium Health, expected in the second quarter of fiscal year 2027.
• Complete the acquisition of Breathe Right, expected in June 2026.
• Continue to increase output and optimize the Pillar5 sterile eye care facility.
• Prioritize debt reduction for the balance of fiscal year 2027.
• Continue to invest in brand building across the diversified portfolio.
• Manage and mitigate energy costs in fiscal year 2027 and beyond.

Key Dates

Recommendation

The company reported a decline in revenue and adjusted EPS compared to the prior year, indicating current operational challenges, particularly with eye care production. However, the acquisition of LaCorium Health is a positive strategic move, and the medium-term outlook suggests potential for significant growth. The current 'hold' recommendation balances the near-term negative performance with the long-term strategic initiatives and projected recovery.

Keywords

Prestige Consumer Healthcare, 8-K Filing, Fiscal 2026 Results, LaCorium Health Acquisition, Consumer Healthcare, Therapeutic Skincare, Earnings Report, Financial Results